This site uses cookies to provide you with a more responsive and personalised service. By using this site you agree to our use of cookies. Please read our cookie notice for more information on the cookies we use and how to delete or block them.

Bookmark Email Print page

    More

    Page   1/2   
  • Measuring the return from Pharmaceutical innovation 2012
    Measuring the return from Pharmaceutical innovation 2012
    This Deloitte report is the third in an annual series exploring the pharmaceutical industry’s performance in generating a return from its investment in new product innovation.
  • Telecare and Telehealth
    'Telecare and Telehealth - A game changer for health and social care’ looks at the role that telecare and telehealth can play in helping to transform health and social care by enabling commissioners and providers to respond effectively to rising demand for health and social care services.
  • 2011 Survey of Health Care Consumers in UK
    2011 Survey of Health Care Consumers in UK
    This is the second consecutive year Deloitte has published research on consumers' behaviors, attitudes and unmet needs based on their personal experiences and observations of the UK health care systems. View all country reports.
  • Measuring the return from innovation
    Measuring the return from innovation
    Last year Deloitte and Thomson Reuters conducted an analysis into value measurement at the "whole R&D business" level using Internal Rate of Return (IRR). This year, we have extended our analysis, looking at the same cohort of companies one year on.
  • Are you agile enough?
    Winning in Life Sciences Are you agile enough?
    Winning in Life Science brochure “Are you agile enough?” is the second iteration of a series which highlights Deloitte’s key propositions to the Life Science and Healthcare industries many and varied challenges.
  • The future of the life sciences industries
    The future of the life sciences industries: Aftermath of the global recession
    The global recession has undoubtedly affected the life sciences industries - the question is whether the impact is temporary or more strategic and lasting?
  • 2010 Survey of Global Health Care Consumers
    Perspective on health care behaviours, attitudes and unmet needs of six countries
    With the state of Healthcare in the UK creating hot debate in the lead up to the May 6th general election, Deloitte has conducted its inaugural study in to Healthcare attitudes and behaviours in the UK. Along with this, five other national studies and an overarching global report have been brought together to form a unique patient perspective.
  • Critical Priorities for the CIO
    Critical Priorities for the CIO
    Deloitte has identified 10 priority areas for the CIO spanning IT effectiveness, IT efficiency and IT capabilities.
  • Funding your future
    Funding your future
    A guide to grants and incentives: understanding the grant system and completion of grant applications can be complicated. We have a team to help.
  • Transformation amid rising risk
    Life sciences companies are waking up to new market realities as they face issues such as patent expiration, competition from generic producers and higher R&D costs. Add to those factors the volatile global economy and one thing is certain: Companies will need to transform to survive.
    • Page   1/2   
Follow:

           Deloitte Blog

© 2013 Deloitte LLP. All rights reserved. Deloitte refers to one or more of Deloitte Touche Tohmatsu Limited, a UK private company limited by guarantee, and its network of member firms, each of which is a legally separate and independent entity.

Please see About Deloitte for a detailed description of the legal structure of Deloitte Touche Tohmatsu Limited and its Member Firms. View our accessibility statement.

Get in touch

More on Deloitte

Highlights